Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD

150.1  -0.72 (-0.48%)

After market: 150.1 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ICLR. ICLR was compared to 55 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on ICLR. With these ratings, ICLR could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ICLR had positive earnings in the past year.
In the past year ICLR had a positive cash flow from operations.
ICLR had positive earnings in each of the past 5 years.
In the past 5 years ICLR always reported a positive cash flow from operatings.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

ICLR's Return On Assets of 4.53% is fine compared to the rest of the industry. ICLR outperforms 76.36% of its industry peers.
Looking at the Return On Equity, with a value of 7.98%, ICLR belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.71%, ICLR is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ICLR is significantly below the industry average of 13.60%.
The last Return On Invested Capital (6.71%) for ICLR is above the 3 year average (5.80%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.53%
ROE 7.98%
ROIC 6.71%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

The Profit Margin of ICLR (9.25%) is better than 76.36% of its industry peers.
ICLR's Profit Margin has declined in the last couple of years.
ICLR has a better Operating Margin (14.54%) than 76.36% of its industry peers.
ICLR's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 29.06%, ICLR is not doing good in the industry: 74.55% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 14.54%
PM (TTM) 9.25%
GM 29.06%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
Compared to 5 years ago, ICLR has more shares outstanding
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ICLR has an Altman-Z score of 1.99. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ICLR (1.99) is comparable to the rest of the industry.
The Debt to FCF ratio of ICLR is 3.23, which is a good value as it means it would take ICLR, 3.23 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ICLR (3.23) is better than 76.36% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that ICLR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.36, ICLR is in line with its industry, outperforming 50.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.23
Altman-Z 1.99
ROIC/WACC0.83
WACC8.11%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

ICLR has a Current Ratio of 1.27. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR has a worse Current ratio (1.27) than 80.00% of its industry peers.
ICLR has a Quick Ratio of 1.27. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.27, ICLR is doing worse than 72.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

ICLR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.85%.
ICLR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.23% yearly.
The Revenue has decreased by -0.48% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)2.85%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-8.07%
Revenue 1Y (TTM)-0.48%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.26%

3.2 Future

ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.55% yearly.
ICLR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.07% yearly.
EPS Next Y-3.13%
EPS Next 2Y2.25%
EPS Next 3Y4.6%
EPS Next 5Y6.55%
Revenue Next Year-3.76%
Revenue Next 2Y-0.87%
Revenue Next 3Y0.97%
Revenue Next 5Y2.07%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 10.94 indicates a reasonable valuation of ICLR.
Based on the Price/Earnings ratio, ICLR is valued cheaper than 100.00% of the companies in the same industry.
ICLR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.45.
ICLR is valuated reasonably with a Price/Forward Earnings ratio of 10.25.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaper than 96.36% of the companies in the same industry.
ICLR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.90.
Industry RankSector Rank
PE 10.94
Fwd PE 10.25
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 100.00% of the companies listed in the same industry.
98.18% of the companies in the same industry are more expensive than ICLR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.27
EV/EBITDA 9.11
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

ICLR has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.72
EPS Next 2Y2.25%
EPS Next 3Y4.6%

More info and screens

0

5. Dividend

5.1 Amount

ICLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (7/3/2025, 7:36:18 PM)

After market: 150.1 0 (0%)

150.1

-0.72 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-23 2025-07-23/amc
Inst Owners101.17%
Inst Owner Change0.89%
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap11.93B
Analysts78.46
Price Target182.58 (21.64%)
Short Float %2.2%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.48%
Min EPS beat(2)-1.19%
Max EPS beat(2)0.23%
EPS beat(4)1
Avg EPS beat(4)-3.85%
Min EPS beat(4)-14.41%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.42%
EPS beat(12)4
Avg EPS beat(12)-1.63%
EPS beat(16)7
Avg EPS beat(16)-0.69%
Revenue beat(2)0
Avg Revenue beat(2)-2.08%
Min Revenue beat(2)-2.61%
Max Revenue beat(2)-1.54%
Revenue beat(4)0
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-1.54%
Revenue beat(8)0
Avg Revenue beat(8)-2.81%
Revenue beat(12)0
Avg Revenue beat(12)-2.47%
Revenue beat(16)0
Avg Revenue beat(16)-2.13%
PT rev (1m)-6.01%
PT rev (3m)-27.7%
EPS NQ rev (1m)0.19%
EPS NQ rev (3m)-4.01%
EPS NY rev (1m)0.13%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-4.41%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-4.65%
Valuation
Industry RankSector Rank
PE 10.94
Fwd PE 10.25
P/S 1.46
P/FCF 11.27
P/OCF 9.71
P/B 1.26
P/tB N/A
EV/EBITDA 9.11
EPS(TTM)13.72
EY9.14%
EPS(NY)14.64
Fwd EY9.75%
FCF(TTM)13.31
FCFY8.87%
OCF(TTM)15.45
OCFY10.29%
SpS103.1
BVpS119.57
TBVpS-38.58
PEG (NY)N/A
PEG (5Y)0.72
Profitability
Industry RankSector Rank
ROA 4.53%
ROE 7.98%
ROCE 8.49%
ROIC 6.71%
ROICexc 6.97%
ROICexgc 100.08%
OM 14.54%
PM (TTM) 9.25%
GM 29.06%
FCFM 12.91%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score7
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.23
Debt/EBITDA 2.08
Cap/Depr 39.01%
Cap/Sales 2.07%
Interest Coverage 250
Cash Conversion 75.48%
Profit Quality 139.54%
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 1.99
F-Score7
WACC8.11%
ROIC/WACC0.83
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)2.85%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-8.07%
EPS Next Y-3.13%
EPS Next 2Y2.25%
EPS Next 3Y4.6%
EPS Next 5Y6.55%
Revenue 1Y (TTM)-0.48%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.26%
Revenue Next Year-3.76%
Revenue Next 2Y-0.87%
Revenue Next 3Y0.97%
Revenue Next 5Y2.07%
EBIT growth 1Y8.27%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.89%
EBIT Next 3Y4.21%
EBIT Next 5Y4.16%
FCF growth 1Y191.78%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y139.85%
OCF growth 3Y15.78%
OCF growth 5Y25.55%